Apogee Therapeutics (APGE) Profit After Tax (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Profit After Tax data on file, last reported at -$74.1 million in Q1 2026.

• On a quarterly basis, Profit After Tax fell 33.92% year-over-year to -$74.1 million in Q1 2026; TTM through Mar 2026 was -$274.5 million, a 33.66% decrease from a year earlier, with the FY2025 full-year figure at -$255.8 million, down 40.44% from the prior year.
• Profit After Tax for Q1 2026 stood at -$74.1 million, down from -$69.3 million in the prior quarter.
• Over the last five years, Profit After Tax for APGE reached as high as -$1.8 million in Q2 2022 and fell as low as -$74.1 million in Q1 2026.
• Historically, Profit After Tax has averaged -$39.5 million across 5 years, with a median of -$33.0 million in 2024.
• Across the five-year window, Profit After Tax slumped 939.92% in 2023 and dropped 3.1% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$14.0 million in 2022, then slumped by 126.57% to -$31.7 million in 2023, then tumbled by 111.81% to -$67.2 million in 2024, then retreated by 3.1% to -$69.3 million in 2025, then dropped by 6.94% to -$74.1 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$74.1 million in Q1 2026, -$69.3 million in Q4 2025, and -$65.0 million in Q3 2025.